Radiopharmaceutical therapy shows favorable results for people with tough-to-treat meningioma brain tumors, Mayo Clinic study finds

The following press release was distributed by the American Society for Radiation Oncology (ASTRO) Phase 2 clinical trial finds 177Lu-Dotatate may extend progression-free survival for patients with no other options to manage recurrent disease WASHINGTON — A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early signs for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor. The nonrandomized phase 2 study’s findings were presented…